title: A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection.
abstract: Cholera is a severe diarrheal disease that may spread rapidly. Vaccination is considered a valid measure against it. We developed a new vaccine candidate, IEM109, against Vibrio cholerae. To generate this candidate, a chromosomal fragment containing the TLC element, attB of the CTX Phi integration site, and RTX cluster responsible for the cytotoxic activity for mammalian cells was deleted through homologous recombination from the previously described El Tor biotype, IEM101. The protective genes ctxB and rstR, which establish resistance to CTX Phi infections, were inserted into that same location on the chromosome of IEM109 to enhance the safety and genetic stability of the vaccine candidate and to prevent horizontal gene transfer. In in vivo tests, cell cultures showed that the cytotoxic effect of IEM109 on Hep-2 was negative. Furthermore, the infection rate of El Tor biotype CTX Phi to that of IEM109 in the rabbit intestine is 3000-fold lower than that of IEM101. Intraintestinal vaccination of rabbits with a single dose of IEM109 elicits high titers of anti-CTB IgG and vibriocidal antibodies. When challenged with 0.5-2 microg CT and 10(5) to 10(8)CFU of four wild toxigenic strains of different biotypes and serogroups, IEM109 conferred full protection. Thus, IEM109 is a stable vaccine candidate that evokes not only antitoxic and vibriocidal immunities, but also resistance to the El Tor biotype CTX Phi infection.
authors.affiliation: State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, PR China.
authors.forename: Meiying
authors.initials: M
authors.lastname: Yan
authors.forename: Guangwen
authors.initials: G
authors.lastname: Liu
authors.forename: Baowei
authors.initials: B
authors.lastname: Diao
authors.forename: Haiyan
authors.initials: H
authors.lastname: Qiu
authors.forename: Lijuan
authors.initials: L
authors.lastname: Zhang
authors.forename: Weili
authors.initials: W
authors.lastname: Liang
authors.forename: Shouyi
authors.initials: S
authors.lastname: Gao
authors.forename: Biao
authors.initials: B
authors.lastname: Kan
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology; D002771:Cholera / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D003001:Cloning, Molecular; D003602:Cytotoxicity, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D007422:Intestines / Q000382:microbiology; D011817:Rabbits; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D041241:Vibrio cholerae O1 / Q000235:genetics / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D022121:Cholera Vaccines; D014614:Vaccines, Synthetic